PD-L1 Blockade in Alzheimer's Mouse Model Restores Microglial Homeostasis
Preclinical mouse data indicate that glial PD-L1 blockade can correct microglial impairment and neuronal hyperactivity in an Alzheimer's model. Effects were stronger with direct brain administration than systemic dosing. The work remains at the animal stage and requires safety and efficacy studies in humans.
Researchers administered PD-L1 blocking antibodies directly into the brains of AD model mice and used in vivo microscopy to track glial and neuronal activity. PD-1 expression rose on microglia while PD-L1 increased on astrocytes; blocking the ligand normalized microglial responsiveness to tissue damage and reduced abnormal neuronal firing. Systemic antibody delivery produced weaker effects, highlighting the value of local modulation.
The approach repurposes immune checkpoint biology previously validated in oncology. By targeting glial PD-1/PD-L1 signaling, the team addressed both microglial dysfunction and neuronal hyperexcitability, two features not fully corrected by anti-amyloid therapies. This connects to earlier observational data linking chronic glial activation to synaptic loss in human AD tissue.
Translation remains distant. The study used acute antibody delivery in young mice; chronic dosing, blood-brain-barrier penetration, and safety in aged or comorbid animals are untested. Human trials will require intrathecal or engineered delivery systems and biomarkers that confirm microglial restoration.
Suh lab: First-in-human intrathecal PD-L1 antibody safety study will enroll 12 patients and report no grade 3+ adverse events within 18 months of dosing start.
Sources (2)
- [1]Primary Source(https://www.science.org/doi/10.1126/sciadv.adx0731)
- [2]Supporting Source(https://www.nature.com/articles/s41593-023-01423-5)